Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 1, 2003 - Issue 3
Submit an article Journal homepage
32
Views
16
CrossRef citations to date
0
Altmetric
Review

A review of tuberculosis: reflections on the past, present and future of a global epidemic disease

Kim Connelly Smith The University of Texas-Houston Medical School, Community General Pediatrics Division, Director, The Children’s Tuberculosis Clinics at, UT-Houston Kid’s Place and Lyndon B Johnson Hospital, 6431 Fannin, MSB 3.150A, Houston, TX 77030, USA. [email protected]
,
Lisa Armitige Division of Infectious Diseases, Department of Internal Medicine, The University of Texas-Houston Medical School, 6431 Fannin, MSB 1.728, Houston, TX77030, USA. [email protected]
&
Audrey Wanger Department of Pathology and Laboratory Medicine, The University of Texas-Houston Medical School, Director, Microbiology Memorial Hermann Hospital, 6431 Fannin, MSB 2.210, Houston, TX 77030, USA. [email protected]
Pages 483-491 | Published online: 10 Jan 2014

References

  • Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country WHO Global Surveillance and Monitoring Project. jAm Med. Assoc 282(7), 677–686 (1999).
  • World Health Organization. The world health report 2000. World Health Organization, Geneva, Switzerland (2000).
  • Floyd K, Blanc L, Raviglione M, Lee JW. Resources required for global tuberculosis control. Science 295(5562), 2040–2041 (2002).
  • Centers for Disease Control and Prevention. Tuberculosis elimination revisited: obstacles, opportunities and a renewed commitment. Advisory Council for the Elimination of Tuberculosis (ACET). MMWR Recomm Rep 48(RR-9), 1–13 (1999).
  • Comstock GW. Variability of tuberculosis trends in a time of resurgence. Clin. Infect. Dis. 19,1015–1022 (1994).
  • Starke JR, Jacobs R, Jereb J. Resurgence of tuberculosis in children. J. Pecliatr 120, 839–855 (1992).
  • Rose AM, Watson JM, Graham C, et al Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998. Thotax56(3), 173–179 (2001).
  • Parslow R, El-Shimy NA, Cundall DB, McKinney PA. Tuberculosis, deprivation and ethnicity in Leeds, UK, 1982–1997. Arch. Dis. Child 84(2), 109–113 (2001).
  • Espinal MA, Laszlo A, Simonsen L, et al Global trends in resistance to antituberculosis drugs. World Health Organization — International Union against Tuberculosis and Lung Disease Working Group on anti-Tuberculosis Drug Resistance Surveillance. N Engl. J. Med 344(17), 1294–1303 (2001).
  • •Highlights the staggering rates of multidrug-resistant TB in certain geographical areas.
  • Reichler MR, Reyes R, Bur S, et al Evaluation of investigations conducted to detect and prevent transmission of tuberculosis. JAIVIA 287(8), 991–995 (2002).
  • Cronin WA, Golub JE, Lathan MJ, et al Molecular epidemiology of tuberculosis in a low-to moderate-incidence state: are contact investigations enough? Emerg. Infect. Dis. 8(11), 1271–1279 (2002).
  • Lienhardt C, Bennett S, Del Prete G, et al Investigation of environmental and host-related risk factors for tuberculosis in Africa. I. Methodological aspects of a combined design. Am. J. Epidemiol 155(11), 1066–1073 (2002).
  • Greenwood CM, Fujiwara TM, Boothroyd LJ, et al Linkage of tuberculosis to chromosome 2q35 loci, including NRAMP1, in a large aboriginal Canadian family. Am. Hum. Genet 67(2), 405–416 (2000).
  • Siddiqui AH, Perl TM, Conlon M, Donegan N, Roghmann MC. Preventing nosocomial transmission of pulmonary tuberculosis: when may isolation be discontinued for patients with suspected tuberculosis? Infect. Contml Hasp. Epidemiol 23(3), 141–144 (2002).
  • Eamranond P, Jaramillo E. Tuberculosis in children: reassessing the need for improved diagnosis in global control strategies. int. J. Tubetrul Lung Dis. 5(7), 594–603 (2001).
  • •Discusses the need for better diagnostic tools for TB in children.
  • Woods GL. The mycobacteriology laboratory and new diagnostic techniques. Infect Dis Clin. N. AM 16(1), 127–144 (2002).
  • ••Comprehensive review of current and newlaboratory diagnostic techniques for tuberculosis are covered in this paper.
  • Hale YM, Pfyffer GE, Salfinger M. Laboratory diagnosis of mycobacterial infections: new tools and lessons learned. Clin. Infect. Dis. 33, 834–846 (2001).
  • Crump JA, Tanner DC, Mirrett S, McKnight CM, Reller LB. Controlled comparison of BACTEC 13A, MYCO/F LYTIC, BacT/Alert MB and ISOLATOR 10 systems for detection of mycobacterium. J. Clin. Microbial. 41, 1987–1990 (2003).
  • Jost KC, Dunbar DF, Barth SS, HEadley VL, Elliott LB. Identification of Mycobacterium tuberculosis and M avium complex directly from smear-positive sputum specimens and BACTEC 12B cultures by high-performance liquid chromatography with fluorescence detection and computer-driven pattern recognition models. J. Clin. Illicmbiol. 33, 1270–1277 (1995).
  • Murray PR (Ed.), ASM Press, DC, USA 560–584 (2003).
  • Centers for Disease Control and Prevention. Update: nucleic acid amplification tests for tuberculosis. MMWR 49(593–594 (2000).
  • Huang T, Huang W, Lee SS, Tu H, Chang S, Liu Y. Rapid detection of pulmonary tuberculosis using the BDProbeTEC ET Mycobacterium tuberculosis complex direct detection assay (DTB). Diagn. Microbial. Inect. Dir. 46,29–33 (2003).
  • Lebrun L, Goullu N, Boutros N, et al Use of INNO-LIPA assay for rapid identification of mycobacteria. Diagn. Mcrobiol Infect. Dis 46,151–153 (2003).
  • Park D, Kim J, Choi K, et al Comparison of polymerase chain reaction with histopathologic features for diagnosis of tuberculosis in formalin-fixed, paraffin-embedded histologic specimens. Arch. Athol Lab. Med 127,326–330 (2003).
  • Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in 114robacterium tuberrulosis• 1998 update. Tuberrul Lung Dis. 79(1), 3–29 (1998).
  • •The genetic basis for resistance to anti-tuberculosis medications as well as rapid diagnostic techniques to detect resistance to tuberculosis drugs is covered in this review.
  • Albay A, Kisa O, Baylan O, Doganci L. The evaluation of FASTPlaqueTB test for the rapid diagnosis of tuberculosis. Diagn. Mcrobiol Infect. Dis 46,211–215 (2003).
  • •A clinical study evaluating a new rapid bacteriophage amplification technique for TB identification compared to culture, PCR and AFB smear.
  • Alcaide F, Gali N, Dominguez J, et al Usefulness of a new mycobacteriophage-based technique for rapid diagnosis of pulmonary tuberculosis. j din. Microbial. 41(7), 2867–2871 (2003).
  • Lee J, Lee CW, Lee S, et al Comparison of polymerase chain reaction with adenosine deaminase activity in pericardial fluid for the diagnosis of tuberculous pericarditis. Am. Med 113,519–521 (2002).
  • Mazurek GH, Villarino ME. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. MMWR 52 (RR-2), 15–18 (2003).
  • ••These CDC guidelines review therecommended use of the new whole blood test for interferon-y for the detection of latent TB infection. The FDA has approved its use in certain populations, yet the test has limitations.
  • Amara RR, Shanti S, Satchidanandam V. Characterization of novel immunodominant antigens of Mycobacterium tuberculosis. Microbiology 144 (Pt 5), 1197–203 (1998).
  • Dillon DC, Alderson MR, Day CH, et al Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG. j Clin. Mcrobiol. 38(9), 3285–3290 (2000).
  • Skeiky YA, Lodes MJ, Guderian JA, et al Cloning, expression and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect. lindrun. 67(8), 3998–4007 (1999).
  • Yuce A, Yucesoy M, Genc S, Sayan M, Ucan ES. Serodiagnosis of tuberculosis by enzyme immunoassay using A60 antigen. Glitz Mcrobiol Infect. 7(7), 372–376 (2001).
  • Wilkinson RJ, Haslov K, Rappuoli R, et al Evaluation of the recombinant —kilodalton antigen of Mycobacterium tuberculosis as a potential immunodiagnostic reagent. j Clin. Mcrobiol 35(3), 553–557 (1997).
  • Lodes MJ, Dillon DC, Mohamath R, et al Serological expression cloning and immunological evaluation of MTB48, a novel Mycobacterium tuberculosis antigen. Clin. Mcrobiol 39(7), 2485–2493 (2001).
  • Lyashchenko K, Colangeli R, Houde M, Al Jahdali H, Menzies D, Gennaro ML. Heterogeneous antibody responses in tuberculosis. Infect. Immun. 66(8), 3936–3940 (1998).
  • Pottumarthy S, Wells VC, Morris AJ. A comparison of seven tests for serological diagnosis of tuberculosis. j Clin. Mcrobiol 38(6), 2227–2231 (2000).
  • •This is a large study comparing seven serological tests for tuberculosis highlighting the limitations of the tests even in combination.
  • Houghton RL, Lodes MJ, Dillon DC, et al Use of multiepitope polyproteins in serodiagnosis of active tuberculosis. Glitz Diagn. Lab. hmmunol. 9(4), 883–891 (2002).
  • •A new test using ELISA to detect multiple antibodies in serum of patients with TB and TB-HIV coinfection is compared with the gold standard.
  • Landowski CP, Godfrey HP, Bentley-Hibbert SI, et al Combinatorial use of antibodies to secreted mycobacterial proteins in a host immune system-independent test for tuberculosis. J. Glitz Mcrobiol 39(7), 2418–2424 (2001).
  • Perkins MD, Conde MB, Martins M, Kritski AL. Serologic diagnosis of tuberculosis using a simple commercial multiantigen assay. Chest 123(1), 107–112 (2003).
  • •A serologic imrnunochromatographic test using five recombinant TB proteins for the detection of pulmonary TB compared with culture and AFB smear performed better in nonHIV coinfected patients than in HIV infected.
  • Uma Devi K, Ramalingam B, Raja A. Antibody response to 114robacterium tuberculasis30 and 16kDa antigens in pulmonary tuberculosis with human immunodeficiency virus coinfection. Diagn. Mcrobiol Infect. Dis 46,205–209 (2003).
  • •An antibody detection test using ELISA for two different antibodies found good results with the 30 ItDa antigen in HIV—TB coinfected patients.
  • Bentley-Hibbert SI, Quan X, Newman T, Huygen K, Godfrey HP Pathophysiology of antigen 85 in patients with active tuberculosis: antigen 85 circulates as complexes with fibronectin and immunoglobulin G. Infect. Immun. 67(2), 581–588 (1999).
  • Choudhry V, Saxena RK. Detection of 114kobacterium tuberculosis antigens in urinary proteins of tuberculosis patients. Eur. j Clin. Microbial. Infect. Dis. 21(1), 1–5 (2002).
  • •This noninvasive study detects antigens in urine samples and compares results with culture positive TB patients versus normal controls with good results.
  • Hamasur B, Bruchfeld J, Haile M, et al Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine. j Microbial. Meth. 45(1), 41–52 (2001).
  • Katti MK. Immunodiagnosis of tuberculous meningitis: rapid detection of mycobacterial antigens in cerebrospinal fluid by reverse passive hemagglutination assay and their characterization by western blotting. FEMS Immunol Med. Microbial. 31 (1), 59–64 (2001).
  • •This study describes a rapid reverse passive hemagglutination (RPHA) test detecting TB antigens in CSF with high sensitivity and specificity.
  • American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. 167, 603–662 (2003).
  • •• Comprehensive, updated recommendations for tuberculosis treatment in the USA.
  • Centers for Disease Control and Prevention. Core Curriculum on tuberculosis What the clinician should know. Department of Health and Human Services, Atlanta (2000).
  • •A straightforward and practical guide for clinicians caring for TB patients. It is well-written with excellent tables and clearly emphasized important information.
  • American Academy of Pediatrics. Tuberculosis. In: Report of the Committee on Infectious Diseases (26th Edition). Pickering LK (Ed.) Red Book: 2003 American Academy of Pediatrics, Elk Grove Village, IL, USA 642–660 (2003).
  • •An important resource for any clinician caring for children with TB, the Red Book is recently updated.
  • Broekmans JF, Migliori GB, Rieder HL, et al European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J. 19(4), 765–775 (2002).
  • •These are guidelines for TB management in low incident countries in Europe, developed by international expert groups.
  • Pablos-Mendez A, Gowda DK, Frieden TR. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Buff. 14brld Health Chgan. 80(6), 489–495; discussion 495–500 (2002).
  • ••Presents an organized approach prioritizingtreatment of TB in developing countries depending on the success of DOTS programs, discussing the risk of escalating problems with MDR-TB if second line drugs are used in poorly functioning programs.
  • Gupta R, Kim JY, Espinal MA, et al Public health. Responding to market failures in tuberculosis control. Science 293(5532), 1049–1051 (2001).
  • Agrawal S, Thomas NS, Dhanikula AB, Kaul CL, Panchagnula R. Antituberculosis drugs and new drug development. CU17: Opin. Pulm. Med. 7(3), 142–147 (2001).
  • American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Aimj Respir Grit. Cate Med 161, S221—S247 (2000).
  • Gordin F, Chaisson RE, Matts JP, et al Rifampin and pyrazinamide vs. isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAIVIA 283(11), 1445–1450 (2000).
  • McNeill L, Allen M, Estrada C, Cook P Pyrazinamide and rifampin vs. isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 123(1), 102–106 (2003).
  • ••This retrospective cohort study finds athreefold increase in hepatotoxicity in patients treated with short course rifampin and pyrazinamide compared to patients treated with 9 months of isoniazid.
  • Jasmer R, Saukkonen J, Blumberg H, et al Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann. Intern Med 137,693–695 (2002).
  • •This multicenter prospective trial shows increased risk of hepatotoxicity with short-course rifampin and pyrazinamide treatment compared with 6 months of isoniazid.
  • Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am j MTh: Grit. Cate Med 167(6), 824–827 (2003).
  • Centers for Disease Control and Prevention. Update: adverse event data and revised American thoracic society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection — United States, 2003. M/V/WR 52(31), 735–739 (2003).
  • Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int. Epiderniol 22 (6), 1154–1158 (1993).
  • Colditz GA, Berkey CS, Mosteller F, et al The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatric596(1 Pt 1), 29–35 (1995).
  • Colditz GA, Brewer TF, Berkey CS, et al Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. jAm Med. Assoc. 271 (9), 698–702 (1994).
  • Zodpey SP, Bansod BS, Shrikhande SN, Maldhure BR, Kulkarni SW Protective effect of Bacillus Calmette Guerin (BCG) against leprosy: a population-based case-control study in Nagpur, India. Lepr Rev 70(3), 287–294 (1999).
  • Cole ST, Brosch R, Parkhill J, et al Deciphering the biology of 4cobacterium tuberculosis from the complete genome sequence. Nature 393(6685), 537–544 (1998).
  • Young DB. Current tuberculosis vaccine development. Gun. Infect. Dir. 30\(Suppl. 3), S254—S256 (2000).
  • •This comprehensive review discusses the current scientific focus and strategies in new vaccine development for TB.
  • Mustafa AS. Biotechnology in the development of new vaccines and diagnostic reagents against tuberculosis. Cur r Phatm Biotechnol 2(2), 157–73 (2001).
  • Shinnick TM. Diagnostic test needs for evaluating antituberculosis vaccines. Gun. Infect. as 30\(Suppl. 3), S276—S278 (2000).
  • Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs 61(1), 9–18 (2001).

Websites

  • Centers for Disease Control and Prevention www.cdc.gov/nchstp/tb.surv/surv2000/defa ult.htm (Viewed August 2003)
  • World Health Organization www.who.int/gtb/publications/ttgnp/PDF/ 2003.313.pdf (Viewed August 2003)
  • The Global Fund to Fight AIDS, Tuberculosis & Malaria www.globalfundatm.org/ (Viewed August 2003)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.